Menu Search
Equities

Qlife Holding AB

4HG:DEU

Qlife Holding AB

Actions
  • Price (EUR)0.006
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+140.00%
  • Beta--
Data delayed at least 15 minutes, as of Jun 14 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Qlife Holding AB is a Sweden-based medical technology Company that manufactures the hardware and software platform Egoo.health (Egoo) with which patients can carry out various types of biomarker tests based on a small amount of blood. Egoo performs analyzes that correlate to over 99 percent with high-performance laboratory instruments. The Egoo instrument measures biomarkers for the chronic diseases Phenylketonuria (PKU), rheumatoid arthritis (RA) and cancer. Qlife Holding is the parent company of the wholly owned Danish medical technology subsidiary Qlife ApS. Qlife ApS develops a medical technology product with the long-term goal of giving people access to safe and valid biomarker data at home.

  • Revenue in SEK (TTM)121.00k
  • Net income in SEK-151.53m
  • Incorporated2019
  • Employees11.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.